logo-loader
Avivagen Inc.

Avivagen commercializing its OxC-beta livestock product around the world

Avivagen Inc (TSXV:VIV) CEO Kym Anthony tells Proactive Investors the Canadian life sciences company has developed and begun commercializing its OxC-beta Livestock product that promotes immune functions in livestock in the the Philippines, Taiwan, New Zealand and Thailand.

Anthony says the product, which has been shown to be effective in replacing the antibiotics added to livestock feeds, will soon be entering the US market.

Quick facts: Avivagen Inc.

Price: $0.53

Market: TSX-V
Market Cap: $18.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Empower Clinics begins trading on the OTCQB under the ticker...

Empower Clinics (CSE: CBDT-OTC: EPWCF) Chairman and CEO Steven McAuley sat down with Steve Darling from Proactive Vancouver to share news the company is now trading in the United States. Empower is now listed on the OTCQB market and McAuley talks about what this means for the company and...

14 hours, 6 minutes ago

2 min read